In CLL, BIRC3, a negative regulator of non-canonical NF-κB, is frequently disrupted, leading to aberrant and constitutive activation of this biological pathway, promoting proliferation and survival [2]. Here, BIRC3 is linked to B-cell chronic lymphocytic leukemia.